Doktorgradsavhandling

• Tandaric, Luka (2025). Rethinking High-Grade Serous Ovarian Carcinoma: Towards Personalized Immunotherapy through Preclinical, Translational and Clinical Evaluation of Combined CD73 and PD-L1 Blockade. (ekstern lenke)

Vitenskapelig artikkel

• Tandaric, Luka; Auranen, Annika; Kleinmanns, Katrin et al. (2025). Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial. (ekstern lenke)
• Caulier, Benjamin William; Joaquina, Sandy; Gelebart, Pascal Francois et al. (2024). CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. (ekstern lenke)
• Mirza, M.R.; Tandaric, Luka; Henriksen, J.R. et al. (2024). NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer. (ekstern lenke)
• Meriranta, Leo; Sorri, Selma; Huse, Kanutte et al. (2024). Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin